Sawai Receives Approval for Vardenafil Tablets
Osaka, Japan – June 3, 2020 – Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Mitsuo Sawai) received approval by the Ministry of Health, Labour and Welfare (MHLW) for Vardenafil tablets (the branded product: LEVITRA®).
Vardenafil tablets are prescribed for the treatment of erectile dysfunction.
The products approved by MHLW on June 3.
|
Product Name: |
VARDENAFIL Tablets 10 mg [SAWAI], 20 mg [SAWAI] |
|
Generic name: |
Vardenafil |
|
Brand products: |
LEVITRA® 10 mg, 20 mg |
The products announced in this press release are not approved by the Food & Drug Administration for sale and distribution in the United States.